View Author
vault patient α- galcer level galcer protein administration cancer number study inkt cells treatment hepatitis vault particles particle expression response nk cells cell lines resistance vault-tube decrease activation vparp placebo effect daunorubicin killer t cells liver serum vault rna trial inkt cell numbers baseline result wild-type vault protein knockout fraction group a-galcer mvp-gfp analysis bone marrow cells killer infection doxorubicin virus probe injection t cells scheper phase tumor increase α- galcer administration fluorescence activity cancer patients α- galactosylceramide efflux formation structure van der vliet vparp-rod hcv rna scheffer immunol function kickhoefer molecule vault rna genes experiment multidrug resistance mvp / change distribution cd 1d ifn -γ hepatitis b
7 Most Recent Publications
|
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection
(Article)
Schneiders, F.L. Scheper, R.J. Blomberg, B.M.E. von Woltman, A.M. Janssen, H.L.A. Eertwegh, A.J.M. van den Verheul, H.M.W. Gruijl, T.D. de Vliet, H.J. van der |
2011-08-01
|
|
α-Galactosylceramide in chronic hepatitis B infection: Results from a randomized placebo-controlled Phase I/ II trial
(Article)
Woltman, A.M. Borg, M.J. ter Janssen, H.L.A. Binda, R.S. Sprengers, D. Blomberg, B.M.E. von Scheper, R.J. Hayashi, K. Nishi, N. Boonstra, A. Molen, R.G. van der |
2009-12-21
|
|
Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C
(Article)
Veldt, B.J. Vliet, H.J. van der Janssen, H.L.A. Nieuwkerk, C.M.J. van Blomberg, B.M.E. von Vlierberghe, H. van Gerken, G. Nishi, N. Hayashi, K. Scheper, R.J. Knegt, R.J. de Eertwegh, A.J.M. van den |
2007-09-01
|
|
Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression.
(Article)
Zon, A. van Mossink, M.H. Schoester, M. Scheper, R.J. Sonneveld, P. Wiemer, E.A.C. |
2004-07-15
|
|
The formation of vault-tubes: a dynamic interaction between vaults and vault PARP
(Article)
Zon, A. van Mossink, M.H. Schoester, M. Houtsmuller, A.B. Scheffer, G.L. Scheper, R.J. Sonneveld, P. Wiemer, E.A.C. |
2003-01-01
|
|
Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics
(Article)
Mossink, M.H. Zon, A. van Fränzel-Luiten, A.A. Schoester, M. Kickhoefer, V.A. Scheffer, G.L. Scheper, R.J. Sonneveld, P. Wiemer, E.A.C. |
2002-01-01
|
|
Multiple human vault RNAs. Expression and association with the vault complex.
(Article)
Zon, A. van Mossink, M.H. Schoester, M. Scheffer, G.L. Scheper, R.J. Sonneveld, P. Wiemer, E.A.C. |
2001-10-05
|
